ESMO 2010 Companies
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumour targeting technology known as the nab® platform and is approved in 39 countries. For more information about the company, please visit www.abraxisbio.com
Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company committed to the development and commercialisation of innovative anti-cancer therapeutics. www.Allos.com
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.To learn more about our pioneering science and vital medicines, visit www.amgen.com
Description: ApoCell is a service provider recognised as a leader in biomarker research, with efforts focused on the identification and analysis of biomarkers and molecular profiling in rare circulating cells. Both standard and proprietary platforms are used to isolate and enrich cell populations of interest, especially circulating tumour cells (CTCs) and circulating epithelial cells (CECs), as well as additional rare cell types including stem cells. Pre-clinical through Phase III studies are currently supported with trial sites world-wide.
AstraZeneca is an innovative pharmaceutical company with a proven record of research and development of treatments for cancer. We are committed to driving pioneering research across a broad range of tumour types. AstraZeneca has a strong development portfolio based on novel, biological targets and a research culture that is enriched by many significant collaborations and partnerships.
Bayer Schering Pharma
As a global organisation with widespread reach and impact, Bayer is applying its experience, knowledge and passion to make life better for oncology patients across the globe. We are dedicated to fulfilling our purpose of discovering innovative cancer-fighting therapies to improve the lives of individuals touched by cancer.
Boehringer Ingelheim GmbH
Building on scientific expertise since 1885 and excellence in various indications, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Boehringer Ingelheim is committed to discovering and developing novel targeted therapies. The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.
Bristol-Myers Squibb mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, heart disease, HIV/AIDS, psychiatric disorders, rheumatoid arthritis, chronic hepatitis B virus infection and diabetes. Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Cephalon is a research based international biopharmaceutical company committed to the discovery, development and marketing of innovative drugs to treat neurological disorders, pain and cancer. Today, Cephalon has an established proprietary portfolio of tyrosine kinase inhibitors along with a recognised expertise in apoptosis and cell signaling, translating our progress in cancer discovery and development into the practice of haematology and oncology.
DAIICHI SANKYO is a global pharmaceutical manufacturer based in Japan. With its roots going back to the year 1899, the company is active in research, development and production of medicines since the early days of the industrialisation of this sector. Oncology is one of the company’s key research areas; the first product in this field has already been launched in 1977.
Definiens is the number one Enterprise Image Intelligence company for analysing and interpreting images. Definiens software supports radiologists in comparing images from different modalities in a consistent and reproducible manner. It provides accurate, automated volumetric quantification over time of almost all organs and lesions. Definiens enables image intelligence along the entire healthcare value chain - from screening to treatment and follow-up imaging.
Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialisation and manufacturing of novel therapeutics. In April 2010, The United States Food and Drug Administration approved Dendreon’s PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
Eisai Europe Limited
Eisai is world leading R&D-based pharmaceutical company. Our human health care (hhc) mission is to “give first thought to patients, their families and to increasing the benefits health care provides”. Eisai is dedicated to discovering, developing and producing innovative oncology therapies. Globally we discover and develop small molecules, therapeutic vaccines, biologic and supportive care agents for cancer across multiple indications.
Elekta’s world leading clinical solutions and management information systems offer high precision treatment of cancer and brain disorders. Used in over 5,000 hospitals globally, more than 100,000 patients daily receive a diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.Elekta’s state of the art tools cover the spectrum of cancer care providing a complete solution for the effective diagnosis, planning, treatment, delivery and follow up of cancer patients www.elekta.com
EUSA Pharma is a rapidly growing transatlantic speciality pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company markets a number of speciality products, including the supersaturated calcium and phosphate mouth rinse Caphosol® for the treatment and prevention of oral mucositis. For more information visit: www.eusapharma.com, www.caphosol.eu or www.mouthsmadegood.com
F Hoffmann-La Roche
Roche is the world’s leading provider of cancer care products, including anti-cancer treatments, supportive care products and diagnostics. Our anticancer medicines include an unprecedented 5 innovative cancer drugs proven to provide survival benefit in 7 different solid tumours including colorectal, gastric, breast, lung, kidney, pancreatic and brain cancers, and 2 haematological cancers - non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Our cancer medicines include: Avastin® (bevacizumab), Herceptin® (trastuzumab), Xeloda® (capecitabine), MabThera® (rituximab) and Tarceva® (erlotinib).
Fresenius Kabi Deutschland GmbH
Fresenius Kabi is focused on therapy and care of critically and chronically ill patients in and outside the hospital. The company offers a broad range of intravenously administered generic drugs across a wide array of therapeutic categories: oncology, anesthesia, analgesia and critical illness. Moreover, Fresenius Kabi’s core product range comprises infusion solutions, blood volume substitutes, parenteral as well as enteral nutrition, and related medical devices.
Fresenius Biotech GmbH
Fresenius Biotech GmbH is a globally operating company dedicated to delivering targeted biopharmaceutical therapies in oncology and transplantation. The recently launched trifunctional antibody Removab® (catumaxomab) represents a new generation of anti-cancer antibodies. It effectively destroys cancer cells from EpCAM-positive carcinomas. Removab® is the first approved causal treatment of malignant ascites in patients with various carcinomas. www.fresenius-biotech.com, www.removab.com
"Gardhen bilance is a company presents in most parts of the world thanks to its exclusive distributors and to high quality of the products. The beds and chairs with or without scales are presents in all privates centres and hospital departments. Gardhen bilance manufactures medical devices and weighing systems in conformity to ISO 9001:2008, ISO 13485:2003, 93/42/CEE. Design, comfort, robust construction is our mission."
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com
Genomic Health (www.genomichealth.com) is focused on the development and commercialisation of genomic-based clinical laboratory services for cancer allowing physicians and patients to make individualised treatment decisions. Genomic Health’s widely adopted OncotypeDX® breast cancer test predicts the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In January 2010, Genomic Health launched its OncotypeDX colon cancer test.
GlaxoSmithKline Oncology is dedicated to pursuing innovations in cancer that will make profound differences in the lives of patients. Through GSK’s bench to bedside approach to research, we are transforming the way therapies are discovered, developed and integrated into clinical care. We have one of the most robust pipelines in the oncology sector. Our worldwide research programme includes collaborations with more than 160 cancer centres.
Helsinn Healthcare SA
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and USA. Helsinn’s business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early to late stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC), development to the filing for and attainment of their market approval worldwide in compliance with FDA and EU requirements. Helsinn’s products are sold directly through the Group’s subsidiaries or out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice. The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn’s cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers. www.helsinn.com
Hospira is a global speciality pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in speciality generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Learn more at www.hospira.com
Imedex is dedicated to improving patient care through educating medical professionals. With high-quality scientific activities, the latest research is translated into clinically-relevant information. Our relationships with leading investigators, researchers and some of the most prestigious societies make our programmes the most effective in the industry. Here, education is the best medicine®.
Informa Healthcare books strives to help the world’s doctors, clinicians, medical researchers, and pharmaceutical scientists improve patient outcomes by providing critical resources written by key opinion leaders in their fields. Our portfolio represents some of the leading brands in medical publishing, including Litt’s, Maudsley, The Medical Directory and popular book series such as Basic and Clinical Oncology.
Janssen-Cilag is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. The company is committed to discovering and delivering innovative medicines for diseases of high unmet medical need and has introduced a range of treatments that make an important difference to the lives of patients with serious health conditions.
Janssen Pharmaceutical Companies of Johnson & Johnson
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. The company is committed to discovering and delivering innovative medicines for diseases of high unmet medical need and has introduced a range of treatments that make an important difference to the lives of patients with serious health conditions.
For more than four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to develop a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care. To learn more about Lilly Oncology’s commitment to cancer, please visit: www.LillyOncology.com
Medscape Oncology is one of the leading online destinations for practising Oncologists and Haematologists providing in-depth clinical resources across breast, lung and colorectal cancers, haematological malignancies, and other cancer types. Medscape Oncology offers the latest medical news, conference coverage, clinical reference tools, and expert perspectives to stay well-informed, including a wide selection of CME courses in Oncology in a variety of formats – all at no cost.
Medtronic Spinal & Biologics Europe
At Medtronic ( www.medtronic.com), we're committed to Innovating for Life by pushing the boundaries of medical technology and actually changing the way the world treats chronic disease. To do that, we're thinking beyond products and beyond the status quo-to continually find more ways to help people live better, longer.
Merck Serono focuses its oncology research on the development of novel therapies that target the tumour cell directly, the tumour environment or the immune system. The monoclonal antibody Erbitux® (cetuximab) specifically blocks the epidermal growth factor receptor (EGFR). The cancer vaccine Stimuvax® (formerly referred to as L-BLP25) and the integrin inhibitor cilengitide are currently undergoing clinical development.
NoemaLife is an Italian-German group whose core mission is the enhancement of clinical processes through workflow automation and process management. Since 1996, NoemaLife has worked alonside high level healthcare organisations assisting them in the fulfilment of their most ambitious IT goals. NoemaLife helps its customers to improve their workflows and to increase their operational efficiency through its cutting edge technology.
Novartis Oncology discovers and develops innovative therapies, including Glivec® (imatinib), Tasigna® (nilotinib), Afinitor® (everolimus) tablets, Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide acetate for injectable suspension) and Exjade® (deferasirox). Novartis has one of the broadest and most comprehensive oncology pipelines in the industry.
For over a decade, Novella Clinical has been an active and flexible partner in supporting the biopharmaceutical and medical device industries with early phase through post-marketing development programmes. From protocol development through to final clinical study report — we integrate deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. We have significant experience in Oncology which has recently been boosted even further by the acquisition of Prologue - a specialist oncology organisation. www.novellaclinical.com
OCT is a full service CRO, operating in Russia, Eastern and Central Europe. OCT main focus is oncology. OCT is well positioned as a boutique CRO of choice to place strategic trials in this region. We have a record of successful trial completion. We are dedicated to speedy recruitment, timely project implementation and individual approach.
Our clinical development programme consists of more than 20 biologics and small molecules with more than 100 ongoing clinical trials, including trials in lung, prostate, breast, renal cell, and haematologic malignancies. Our diverse portfolio includes a number of approved therapies in a range of cancers, including gastrointestinal stromal tumours, renal cell carcinoma, as well as breast, colon, and rectal cancer.
Pharmacosmos works to improve treatment options for healthcare professionals and patients suffering from iron deficiency. An independent company with an ongoing R&D programme, it collaborates with exclusive partners to market its medicines in more than 50 countries. Pharmacosmos’ new treatment for iron deficiency anaemia, Monofer®, has recently received marketing authorisation in 22 countries in Europe.
PharmaMar's mission is to advance cancer care through the discovery, development and commercialisation of innovative marine-derived medicines.PharmaMar is a Spanish member of Grupo Zeltia, a leader in the development of antitumour drugs of marine origin. Its first product on the market, Yondelis® is the first Spanish antitumoural developed by a company that receives approval from the EMA.
Pierre Fabre Medicament
Pierre Fabre Medicament : 9700 people, 2008 turnover : €1,75 billions. Within Pierre Fabre Oncology, our main product, Navelbine (Breast and Lung cancer) with both IV and oral forms, has treated more than 1 million patients since its launch. New comers in our portfolio, Javlor, second line bladder cancer, and Busilvex, in haematology, are already available in several European countries.
PRA International is a leading global CRO, conducting clinical trials in over 75 countries, across all phases of drug development. With significant expertise in Oncology and Haematology PRA has been instrumental in the successful approvals of life-extending cancer drugs and has considerable expertise in breast cancer, colorectal cancer, NSCLC, pancreatic cancer, and renal cell cancer.
Premier Research Group Limited
Premier Research is a leading, global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trials services of the highest quality for biopharmaceutical and medical device companies. Premier Research has a broad base of oncology experience that covers the full spectrum of cancer-related therapeutic indications.
prIME Oncology is a global professional Independent Medical Education organisation specialising in educational activities for physicians that treat patients with cancer. With the ultimate goal of improving patient outcomes, prIME Oncology provides evidence-based, state-of-the-art educational activities that assist oncology clinicians in making up-to-date and appropriate treatment decisions
QIAGEN, leaders in the field of personalised healthcare, have launched the therascreen® range of companion diagnostics which detect mutations in key oncogenes, utilise a range of detection technologies and provide fully supported, integrated workflows.PreAnalytiX, a QIAGEN/BD JV company, offer various systems, including the PAXgene® Tissue System which both fixes tissue samples for histomorphology, and preserves biomolecules for molecular analysis.
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.
Sandoz, a division of Novartis, is a worldwide leader in the rapidly growing generics industry and the global pioneer of biosimilars. Sandoz derives competitive advantage from its expertise in differentiated products, ranging from complex generics to biosimilars, and from its extensive global presence. It comprises a Retail Generics business and three specialised business units focusing on biopharmaceuticals, oncology injectables, and anti-infectives.
Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit www.sanofi-aventis.us or www.sanofi-aventis.com
Sigma-Tau is a leading research-based Italian pharmaceutical company, with annual revenues of € 613 million in 2008 and over 2400 employees worldwide. Therapeutic areas in which the company’s research and development are focused include cardiovascular and metabolic diseases, central and peripheral neurological diseases, oncology and immunology. Sigma-Tau has operating subsidiaries throughout Europe and the US and maintains a presence in all of the world’s major pharmaceutical markets.
Sintesi Research Srl
Sintesi Research is a full-service clinical research organisation headquartered in Milan, with regional offices in Rome and Glendale, Los Angeles, USA.We provide pharmaceutical, biotechnology and medical device companies with a broad range of outsourced services in planning, running and reporting phase I-IV trials and supporting post approval development with safety surveillance studies, observational studies and registries.
SpePharm Holding B.V.
SpePharm is a pan-European speciality pharmaceutical company active in the hospital and specialist segments. The company is focusing on products within oncology, haematology, critical and supportive care. The products currently marketed by SpePharm in Europe are Savene®, Dantrium®, MuGard®, Xerotin® and PROther®.
We are Synovate Healthcare — the global healthcare market research specialists of Synovate. We are 550+ experts working across 4 continents to help the global pharmaceutical and medical device industries achieve their business objectives. Why work with us? It's not just that we combine therapy area expertise with innovative research thinking, or that we bring global reach together with local understanding. It's our passionate and entrepreneurial spirit, which ensures the attention to detail and flexibility you'd expect from a small agency.
Takeda Pharmaceuticals Europe Ltd
Takeda is a global research-based pharmaceutical company. Our mission is better health for patients worldwide through leading innovation in medicine. With oncology a key area of focus, our innovation will result in the discovery, development and delivery of high-quality, differentiated products focused on patient needs.
Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centres and medical oncology practices. Varian Medical Systems employs approximately 5,000 people. For more information, visit www.varian.com
Vifor Pharma, headquartered in Switzerland, is the world leader in iron preparations for the treatment of iron deficiency (ID) and iron deficiency anaemia (IDA). Its two major drugs are:
- Ferinject® (ferric carboxymaltose), an innovative i.v. iron addressing unmet clinical needs and optimising the management of ID/IDA in cancer patients
- Venofer® (iron sucrose), the most established i.v. iron preparation